<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32330425</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1934-6069</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>Cell host &amp; microbe</Title><ISOAbbreviation>Cell Host Microbe</ISOAbbreviation></Journal><ArticleTitle>Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence.</ArticleTitle><Pagination><StartPage>736</StartPage><EndPage>751.e8</EndPage><MedlinePgn>736-751.e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chom.2020.04.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1931-3128(20)30230-4</ELocationID><Abstract><AbstractText>The live-attenuated oral poliovirus vaccine (OPV or Sabin vaccine) replicates in gut-associated tissues, eliciting mucosa and systemic immunity. OPV protects from disease and limits poliovirus spread. Accordingly, vaccination with OPV is the primary strategy used to end the circulation of all polioviruses. However, the ability of OPV to regain replication fitness and establish new epidemics represents a significant risk of polio re-emergence should immunization cease. Here, we report the development of a poliovirus type 2 vaccine strain (nOPV2) that is genetically more stable and less likely to regain virulence than the original Sabin2 strain. We introduced modifications within at the 5' untranslated region of the Sabin2 genome to stabilize attenuation determinants, 2C coding region to prevent recombination, and 3D polymerase to limit viral adaptability. Prior work established that nOPV2 is immunogenic in preclinical and clinical studies, and thus may enable complete poliovirus eradication.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Ming Te</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bujaki</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Institute for Biological Standards and Control (NIBSC), South Mimms, Herts EN6 3QG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolan</LastName><ForeName>Patrick T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Institute for Biological Standards and Control (NIBSC), South Mimms, Herts EN6 3QG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahid</LastName><ForeName>Rahnuma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konz</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Amy J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Bill and Melinda Gates Foundation, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Bill and Melinda Gates Foundation, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Coster</LastName><ForeName>Ilse</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revets</LastName><ForeName>Hilde</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macadam</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute for Biological Standards and Control (NIBSC), South Mimms, Herts EN6 3QG, UK. Electronic address: andrew.macadam@nibsc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andino</LastName><ForeName>Raul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: raul.andino@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01AI40085</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI091575</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI036178</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Host Microbe</MedlineTA><NlmUniqueID>101302316</NlmUniqueID><ISSNLinking>1931-3128</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="C090443">polymerase 3Dpol, poliovirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 Nov;587(7832):15-16. doi: 10.1038/d41586-020-03045-2</RefSource><PMID Version="1">33122836</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005818" MajorTopicYN="N">Genetic Engineering</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011995" MajorTopicYN="N">Recombination, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OPV2</Keyword><Keyword MajorTopicYN="N">Sabin 2p</Keyword><Keyword MajorTopicYN="N">live-attenuated vaccine</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">poliovirus eradication</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32330425</ArticleId><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2020.04.003</ArticleId><ArticleId IdType="pii">S1931-3128(20)30230-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acevedo A., Brodsky L., Andino R. Mutational and fitness landscapes of an RNA virus revealed through population sequencing. Nature. 2014;505:686&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4111796</ArticleId><ArticleId IdType="pubmed">24284629</ArticleId></ArticleIdList></Reference><Reference><Citation>Asturias E.J., Bandyopadhyay A.S., Self S., Rivera L., S&#xe1;ez-Llorens X., Lopez E., Melgar M., Gaensbauer J.T., Weldon W.C., Oberste M.S., Latin American IPV001BMG Study Group Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">27212429</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay A.S., Garon J., Seib K., Orenstein W.A. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake I.M., Pons-Salort M., Molodecky N.A., Diop O.M., Chenoweth P., Bandyopadhyay A.S., Zaffran M., Sutter R.W., Grassly N.C. Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine. N.&#xa0;Engl. J. Med. 2018;379:834&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985919</ArticleId><ArticleId IdType="pubmed">30157398</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Shaw J., Jorba J., Bukbuk D., Adu F., Gumede N., Pate M.A., Abanida E.A., Gasasira A., Iber J. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J.&#xa0;Virol. 2013;87:4907&#x2013;4922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624331</ArticleId><ArticleId IdType="pubmed">23408630</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Diop O.M., Sutter R.W., Kew O.M. Vaccine-derived polioviruses. J.&#xa0;Infect. Dis. 2014;210(Suppl 1):S283&#x2013;S293.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrill C.P., Strings V.R., Andino R. Poliovirus: generation, quantification, propagation, purification, and storage. Curr Protoc Microbiol. 2013;29:15H&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826561</ArticleId><ArticleId IdType="pubmed">23686830</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao L. Fitness of RNA virus decreased by Muller&#x2019;s ratchet. Nature. 1990;348:454&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">2247152</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark M.F., Lister R.M., Bar-Joseph M. ELISA techniques. Methods Enzymol. 1986;118:742&#x2013;766.</Citation></Reference><Reference><Citation>Contreras G., Dimock K., Furesz J., Gardell C., Hazlett D., Karpinski K., McCorkle G., Wu L. Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals. 1992;20:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">1319179</ArticleId></ArticleIdList></Reference><Reference><Citation>Curigliano G. Cancer Evolution as the New Frontier of Precision Medicine. Handb. Exp. Pharmacol. 2018;249:289&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">30406442</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis L.E., Bodian D., Price D., Butler I.J., Vickers J.H. Chronic progressive poliomyelitis secondary to vaccination of an immunodeficient child. N.&#xa0;Engl. J. Med. 1977;297:241&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">195206</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., Holland J. Raven Press; New York: 1994. Mutations and rapid evolution of RNA viruses.</Citation></Reference><Reference><Citation>Domingo E., Martin V., Perales C., Grande-P&#xe9;rez A., Garc&#xed;a-Arriaza J., Arias A. Viruses as quasispecies: biological implications. Curr. Top. Microbiol. Immunol. 2006;299:51&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7120838</ArticleId><ArticleId IdType="pubmed">16568896</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte E., Clarke D., Moya A., Domingo E., Holland J. Rapid fitness losses in mammalian RNA virus clones due to Muller&#x2019;s ratchet. Proc. Natl. Acad. Sci. USA. 1992;89:6015&#x2013;6019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC402129</ArticleId><ArticleId IdType="pubmed">1321432</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G., Begg N.T., Cammack N., Minor P.D. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J.&#xa0;Med. Virol. 1990;32:92&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">2177777</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans D.M., Dunn G., Minor P.D., Schild G.C., Cann A.J., Stanway G., Almond J.W., Currey K., Maizel J.V., Jr. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature. 1985;314:548&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">2986004</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher R.A. Oxford Univ. Press; Oxford, UK: 1930. The Genetical Theory of Natural Selection.</Citation></Reference><Reference><Citation>Goodfellow I., Chaudhry Y., Richardson A., Meredith J., Almond J.W., Barclay W., Evans D.J. Identification of a cis-acting replication element within the poliovirus coding region. J.&#xa0;Virol. 2000;74:4590&#x2013;4600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111979</ArticleId><ArticleId IdType="pubmed">10775595</ArticleId></ArticleIdList></Reference><Reference><Citation>Guest S., Pilipenko E., Sharma K., Chumakov K., Roos R.P. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J.&#xa0;Virol. 2004;78:11097&#x2013;11107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC521805</ArticleId><ArticleId IdType="pubmed">15452230</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm S. A simple sequentially rejective multiple test procedure. Scand Stat Theory Appl. 2019;6:65&#x2013;70.</Citation></Reference><Reference><Citation>Jorba J., Diop O.M., Iber J., Henderson E., Zhao K., Sutter R.W., Wassilak S.G.F., Burns C.C. Update on Vaccine-Derived Polioviruses - Worldwide, January 2017-June 2018. MMWR Morb. Mortal. Wkly. Rep. 2018;67:1189&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6290814</ArticleId><ArticleId IdType="pubmed">30359342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauder S.E., Racaniello V.R. Poliovirus tropism and attenuation are determined after internal ribosome entry. J.&#xa0;Clin. Invest. 2004;113:1743&#x2013;1753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC420511</ArticleId><ArticleId IdType="pubmed">15199409</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O.M., Nottay B.K. Molecular epidemiology of polioviruses. Rev. Infect. Dis. 1984;6(Suppl 2):S499&#x2013;S504.</Citation><ArticleIdList><ArticleId IdType="pubmed">6330846</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O., Morris-Glasgow V., Landaverde M., Burns C., Shaw J., Garib Z., Andr&#xe9; J., Blackman E., Freeman C.J., Jorba J. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296:356&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896235</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 2005;59:587&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlson S., Burlison J., Giles E., Fox H., Macadam A.J., Minor P.D. New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication. PLoS Pathog. 2015;11:e1005316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4699825</ArticleId><ArticleId IdType="pubmed">26720150</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt Jennifer, Campagnoli Ray, Vincent Annelet, Shaw Jing, Wei Ling, Wynn Nhien, Smithee Shane, Bujaki Erika, Yeh Ming Te, Laassri Majid, Zagorodnyaya Tatiana, Weiner Amy, Chumakov Konstantin, Andino Raul, Macadam Andrew, Kew Olen, Burns Cara. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020 doi: 10.1038/s41541-020-0176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0176-7</ArticleId><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkova E., Laassri M., Zagorodnyaya T., Petrovskaya S., Rodionova E., Cherkasova E., Gmyl A., Ivanova O.E., Eremeeva T.P., Lipskaya G.Y. Pressure for Pattern-Specific Intertypic Recombination between Sabin Polioviruses: Evolutionary Implications. Viruses. 2017;9:353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5707560</ArticleId><ArticleId IdType="pubmed">29165333</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauring A.S., Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010;6:e1001005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908548</ArticleId><ArticleId IdType="pubmed">20661479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauring A.S., Jones J.O., Andino R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 2010;28:573&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2883798</ArticleId><ArticleId IdType="pubmed">20531338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenski R.E., Mongold J.A., Sniegowski P.D., Travisano M., Vasi F., Gerrish P.J., Schmidt T.M. Evolution of competitive fitness in experimental populations of E. coli: what makes one genotype a better competitor than another? Antonie van Leeuwenhoek. 1998;73:35&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">9602277</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowry K., Woodman A., Cook J., Evans D.J. Recombination in enteroviruses is a biphasic replicative process involving the generation of greater-than genome length &#x2018;imprecise&#x2019; intermediates. PLoS Pathog. 2014;10:e1004191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055744</ArticleId><ArticleId IdType="pubmed">24945141</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam A.J., Ferguson G., Burlison J., Stone D., Skuce R., Almond J.W., Minor P.D. Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology. 1992;189:415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">1641974</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam A.J., Stone D.M., Almond J.W., Minor P.D. The 5&#x2032; noncoding region and virulence of poliovirus vaccine strains. Trends Microbiol. 1994;2:449&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">7866703</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam A.J., Ferguson G., Stone D.M., Meredith J., Knowlson S., Auda G., Almond J.W., Minor P.D. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J.&#xa0;Virol. 2006;80:8653&#x2013;8663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1563845</ArticleId><ArticleId IdType="pubmed">16912313</ArticleId></ArticleIdList></Reference><Reference><Citation>Manor Y., Handsher R., Halmut T., Neuman M., Bobrov A., Rudich H., Vonsover A., Shulman L., Kew O., Mendelson E. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. J.&#xa0;Clin. Microbiol. 1999;37:1670&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC84919</ArticleId><ArticleId IdType="pubmed">10325305</ArticleId></ArticleIdList></Reference><Reference><Citation>McKnight K.L., Lemon S.M. Capsid coding sequence is required for efficient replication of human rhinovirus 14 RNA. J.&#xa0;Virol. 1996;70:1941&#x2013;1952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190023</ArticleId><ArticleId IdType="pubmed">8627720</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor P.D. Polio vaccines and the eradication of poliomyelitis. Lancet. 2012;380:454&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">22766208</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor P., Dunn G., Almond J.W., MacAdam A. Measles and Poliomyelitis. Springer Vienna; 1993. Stability of attenuated poliovirus strain genotypes in the human intestinal tract; pp. 391&#x2013;399.</Citation></Reference><Reference><Citation>Neverov A., Chumakov K. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. Proc. Natl. Acad. Sci. USA. 2010;107:20063&#x2013;20068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993378</ArticleId><ArticleId IdType="pubmed">21041640</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallansch M.A. Ending Use of Oral Poliovirus Vaccine - A Difficult Move in the Polio Endgame. N.&#xa0;Engl. J. Med. 2018;379:801&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083018</ArticleId><ArticleId IdType="pubmed">30157390</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer J.K., Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. USA. 2003;100:7289&#x2013;7294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165868</ArticleId><ArticleId IdType="pubmed">12754380</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt L.R., Est&#xed;variz C.F., Sutter R.W. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J.&#xa0;Infect. Dis. 2014;210(Suppl 1):S380&#x2013;S389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio Global Eradication Initiative  This Week. 2020. http://polioeradication.org/polio-today/polio-now/this-week/</Citation></Reference><Reference><Citation>Pollard S.R., Dunn G., Cammack N., Minor P.D., Almond J.W. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J.&#xa0;Virol. 1989;63:4949&#x2013;4951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC251143</ArticleId><ArticleId IdType="pubmed">2552175</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy B.Y., Miller D.M., Tsao H. Somatic driver mutations in melanoma. Cancer. 2017;123(S11):2104&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pubmed">28543693</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts L. Polio outbreaks in the DRC threaten eradication effort. Science. 2018;361:10&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">29976803</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouzine I.M., Rodrigo A., Coffin J.M. Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol. Mol. Biol. Rev. 2001;65:151&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC99023</ArticleId><ArticleId IdType="pubmed">11238990</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe A., Ferguson G.L., Minor P.D., Macadam A.J. Coding changes in the poliovirus protease 2A compensate for 5&#x2019;NCR domain V disruptions in a cell-specific manner. Virology. 2000;269:284&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">10753707</ArticleId></ArticleIdList></Reference><Reference><Citation>Roze D., Barton N.H. The Hill-Robertson effect and the evolution of recombination. Genetics. 2006;173:1793&#x2013;1811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1526660</ArticleId><ArticleId IdType="pubmed">16702422</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern A., Yeh M.T., Zinger T., Smith M., Wright C., Ling G., Nielsen R., Macadam A., Andino R. The Evolutionary Pathway to Virulence of an RNA Virus. Cell. 2017;169:35&#x2013;46.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787669</ArticleId><ArticleId IdType="pubmed">28340348</ArticleId></ArticleIdList></Reference><Reference><Citation>Svitkin Y.V., Cammack N., Minor P.D., Almond J.W. Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472----U. Virology. 1990;175:103&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">2155504</ArticleId></ArticleIdList></Reference><Reference><Citation>Temko D., Tomlinson I., Severini S., Schuster-Boeckler B., Graham T. The effects of mutational process and selection on driver mutations across cancer types. Nat Commun. 2017;9:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5945620</ArticleId><ArticleId IdType="pubmed">29748584</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson K.M., Kalkowska D.A. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV) Expert Rev. Vaccines. 2019;18:725&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816497</ArticleId><ArticleId IdType="pubmed">31248293</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., De Coster I., Bandyopadhyay A.S., Revets H., Withanage K., De Smedt P., Suykens L., Oberste M.S., Weldon W.C., Costa-Clemens S.A. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature. 2006;439:344&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1569948</ArticleId><ArticleId IdType="pubmed">16327776</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilm A., Aw P.P., Bertrand D., Yeo G.H., Ong S.H., Wong C.H., Khor C.C., Petric R., Hibberd M.L., Nagarajan N. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012;40:11189&#x2013;11201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526318</ArticleId><ArticleId IdType="pubmed">23066108</ArticleId></ArticleIdList></Reference><Reference><Citation>Worobey M., Holmes E.C. Evolutionary aspects of recombination in RNA viruses. J.&#xa0;Gen. Virol. 1999;80:2535&#x2013;2543.</Citation><ArticleIdList><ArticleId IdType="pubmed">10573145</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Rouzine I.M., Bianco S., Acevedo A., Goldstein E.F., Farkov M., Brodsky L., Andino R. RNA Recombination Enhances Adaptability and Is Required for Virus Spread and Virulence. Cell Host Microbe. 2016;19:493&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840895</ArticleId><ArticleId IdType="pubmed">27078068</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Dolan P.T., Goldstein E.F., Li M., Farkov M., Brodsky L., Andino R. Poliovirus intrahost evolution is required to overcome tissue-specific innate immune responses. Nat. Commun. 2017;8:375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5575128</ArticleId><ArticleId IdType="pubmed">28851882</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Rouzine I.M., Bianco S., Acevedo A., Goldstein E.F., Farkov M., Brodsky L., Andino R. RNA Recombination Enhances Adaptability and Is Required for Virus Spread and Virulence. Cell Host Microbe. 2017;22:420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5807061</ArticleId><ArticleId IdType="pubmed">28910639</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. (2015). WHO SOP for neurovirulence testing of Oral Polio Vaccine using TgPVR21 transgenic mice. https://www.who.int/biologicals/vaccines/POLIO_SOP_TgmNVT_SOPv7_30_June2015_CLEAN2.pdf?ua=1.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>